The role of traditional herbal medicine for ischemic stroke: from bench to clinic—A critical review

• Published in: Phytomedicine (Stuttgart) 2023-01, Vol.109, p.154609-154609, Article 154609
• Main Authors: Hao, Dan-Li, Li, Jia-Meng, Xie, Ran, Huo, Hai-Ru, Xiong, Xing-jiang, Sui, Feng, Wang, Peng-qian
• Format: Article
• Language: English
• Subjects: Clinical efficacy; Complementary Therapies; Drugs, Chinese Herbal - adverse effects; Humans; Ischemic stroke; Ischemic Stroke - drug therapy; Medicine, Chinese Traditional; Medicine, Traditional; Pharmacological mechanisms; Stroke - drug therapy; Traditional Chinese medicine
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2022.154609

Ischemic stroke (IS) is a leading cause of death and severe long-term disability worldwide. Over the past few decades, considerable progress has been made in anti-ischemic therapies. However, IS remains a tremendous challenge, with favourable clinical outcomes being generally difficult to achieve from candidate drugs in preclinical phase testing. Traditional herbal medicine (THM) has been used to treat stroke for over 2,000 years in China. In modern times, THM as an alternative and complementary therapy have been prescribed in other Asian countries and have gained increasing attention for their therapeutic effects. These millennia of clinical experience allow THM to be a promising avenue for improving clinical efficacy and accelerating drug discovery. To summarise the clinical evidence and potential mechanisms of THMs in IS. A comprehensive literature search was conducted in seven electronic databases, including PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the Chinese National Knowledge Infrastructure, the VIP Information Database, the Chinese Biomedical Literature Database, and the Wanfang Database, from inception to 17 June 2022 to examine the efficacy and safety of THM for IS, and to investigate experimental studies regarding potential mechanisms. THM is widely prescribed for IS alone or as adjuvant therapy. In clinical trials, THM is generally administered within 72 h of stroke onset and are continuously prescribed for over 3 months. Compared with Western medicine (WM), THM combined with routine WM can significantly improve neurological function defect scores, promote clinical total effective rate, and accelerate the recovery time of stroke with fewer adverse effects (AEs). These effects can be attributed to multiple mechanisms, mainly anti-inflammation, antioxidative stress, anti-apoptosis, brain blood barrier (BBB) modulation, inhibition of platelet activation and thrombus formation, and promotion of neurogenesis and angiogenesis. THM may be a promising candidate for IS management to guide clinical applications and as a reference for drug development.